Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Summary

This is a single-arm, open-label, single-dose, dose-escalation exploratory study to evaluate the safety and tolerability of a single dose of YOLT-202 in patients with AATD and determine the optimal biologically active dose (OBD) of YOLT-202.

Timeline

Start

2025-06-18

Primary completion

2027-01

Completion

2027-03

Drugs

Indications